Zacks Investment Research lowered shares of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) from a buy rating to a hold rating in a report issued on Saturday morning.

According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “

RTTR has been the topic of a number of other reports. Maxim Group reaffirmed a hold rating on shares of Ritter Pharmaceuticals in a research note on Wednesday, July 5th. Chardan Capital dropped their price objective on shares of Ritter Pharmaceuticals from $3.50 to $1.50 and set a buy rating on the stock in a research note on Tuesday, August 8th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $4.88.

Shares of Ritter Pharmaceuticals (NASDAQ RTTR) opened at 0.532 on Friday. The company’s market capitalization is $7.85 million. The firm’s 50-day moving average is $0.56 and its 200 day moving average is $0.92. Ritter Pharmaceuticals has a 12 month low of $0.51 and a 12 month high of $3.75.

Ritter Pharmaceuticals (NASDAQ:RTTR) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.14). Equities research analysts predict that Ritter Pharmaceuticals will post ($0.42) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/19/ritter-pharmaceuticals-inc-rttr-cut-to-hold-at-zacks-investment-research.html.

An institutional investor recently raised its position in Ritter Pharmaceuticals stock. KCG Holdings Inc. raised its holdings in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 105,409 shares of the biotechnology company’s stock after buying an additional 76,046 shares during the period. KCG Holdings Inc. owned about 0.91% of Ritter Pharmaceuticals worth $150,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 7.55% of the company’s stock.

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Get a free copy of the Zacks research report on Ritter Pharmaceuticals (RTTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Stock Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.